openPR Logo
Press release

Ascariasis Treatment & Management Market Opportunities, Trends and Forecast by 2025

07-24-2017 04:09 PM CET | Health & Medicine

Press release from: TMR - Research Reports

Ascariasis Treatment & Management Market Opportunities,

Ascariasis is one of the most common helminthic infections in humans worldwide. The diseases is caused by the Ascaris lumbricoids, the largest nematode residing in the alimentary canal of humans. Ascariasis is endemic in the tropical and subtropical regions of the world with low standard of public health and hygiene. The center for diseases control and prevention (CDC) states that, approximately, 0.8-1.2 billion of the global population is infected with Ascaris lumbricoids currently. Usually, asymptomatic, Ascariasis commonly infects children’s and results in 3000–60 000 deaths every year, usually as a result of intestinal obstruction. Ascaris lives in the intestine and is passed through feces of the infected individual. Ascaris is transmitted by accidental ingestion of food, water and soil contaminated with Ascaris eggs. Ascaris infected individuals often do not show any symptoms. However, mild symptoms such as abdominal discomfort and cough may occur in some individuals. Cough in Ascariasis is generally due to the migration of the worm through the body. Several other symptoms such as, intestinal blockage and impaired growth in children’s are perceptive in case of individuals with chronic Ascaris infection. Diagnosis of Ascariasis infection is done by visual examination of the Ascaris eggs or adult worms in the stool sample under the microscope. Anthelminthic medications, such as albendazole and mebendazole are highly recommended medications for treatment of Ascaris infection. According to the WHO, children’s with the Ascariasis prevalence exceeding 70% need to be treated once in a year, however, WHO advices a targeted treatment two to three times a year in case the helminthes is harboring an adult.

Read the Comprehensive Overview of Ascariasis Treatment & Management Market: http://www.transparencymarketresearch.com/ascariasis-treatment-management-market.html

Poor personal hygiene and poor sanitation in underdeveloped countries is the prime factor contributing towards rising prevalence of this disease. However, adults are known to harbor the helminthes at a low intensity whereas the disease is highly prevalent in children’s. Accidental contact with soil contaminated with human feces, including with human fecal matter leads to spread of this disease among humans. Several health education initiatives conducted by CDC and World Health Organization (WHO) to reduce morbidity as opposed to eradicate helminthes is the prime area of concerns. Measures such as, maintenance of personal hygiene, implementing effective sewage disposal systems, avoiding open defection are few of the factors that will help to prevent the disease.

The global market for Ascariasis treatment & management is segmented on basis of treatment type, distribution channel, and geography:

Segmentation by Product Type

Anti-parasite medications
Surgery

Segmentation by Distribution Channel

Hospital Pharmacies
Retail Pharmacies
E-Commerce

Increasing administration of contaminated water and food has resulted in increasing number of childerns affecting from this diseases. Drugs including, albendazole, levamisole, mebendazole, piperazine, and pyrantel pamoate are the primary drugs used to treat Ascariasis. Pyrantel pamoate, is highly recommended for women’s who are pregnant. However, in some cases broad spectrum antibiotics are also the choice of treatment.

By treatment type, the global market for Ascariasis Treatment & Management has been classified into, anti-parasite medications and surgery. Surgery is recommended therapy in case of severe intestinal blockage with Ascaris. Currently, there is no vaccine for treatment of Ascaris infection.

On the basis of distribution channel, the global Ascariasis Treatment & Management market is segmented into, hospital pharmacies, retail pharmacies and e-commerce.

On the basis of regional presence, global Ascariasis Treatment & Management market is segmented into five key regions viz. North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. The disease is found to be prevalent in Middle East and African countries with low socioeconomic status and poor personal hygiene. For example, the disease is found to affect a large proportion of population in Ethiopia. Latin America is expected to be second most prevalent region. Furthermore, south East Asian counters including, Indonesia, Malaysia, Thailand, Vietnam, Philippines are also one of the highly affected counties. The Ascariasis treatment and management market is expected to remain dominated in tropical and subtropical regions of the world. This is largely attributed to high prevalence of the disease in such countries. However, the Ascariasis treatment and management market in North America is expected to be on the lower side due to increased level of awareness in maintaining the personal hygiene.

Request for the Sample Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=22688

Some of the major players operating in global Ascariasis Treatment & Management market are, Johnson & Johnson Services, Inc, Amedra Pharmaceuticals LLC., Cipla Inc., Cadila Pharmaceuticals Ltd., Quartz Pharmaceuticals, LLC, Merck & Co., Inc., Romark Laboratories. Companies are involved in collaboration agreements for R&D in order to exploit maximum revenue potential in global Ascariasis Treatment & Management market.

About TMR

Transparency Market Research (TMR) is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Ascariasis Treatment & Management Market Opportunities, Trends and Forecast by 2025 here

News-ID: 638864 • Views:

More Releases from TMR - Research Reports

Pulmonary Drugs Market is Expected to Reach US$ 28,082.1 Million by the End of 2024
Pulmonary Drugs Market is Expected to Reach US$ 28,082.1 Million by the End of 2 …
According to the research report, the global pulmonary drugs market is expected to be worth US$ 28,082.1 mn by the end of 2024 as compared to US$ 48,039.7 mn in 2015. Analysts calculate that the global market will plummet at a CAGR of -6.3% during the forecast period of 2016 and 2024. The market will thrive as the demand for combination drugs is anticipated to remain on the rise during
North America Ventricular Assist Device Market is rising to a valuation of US$ 1.07 Billion by 2024
North America Ventricular Assist Device Market is rising to a valuation of US$ 1 …
According to TMR, the opportunity in the North America market for VADs, which stood at US$0.4 bn in 2015, is likely to expand at a healthy CAGR of 9.20% between 2016 and 2024 and increase to US$1.07 bn by the end of the forecast period. The destination therapy (DT) segment has been reporting a greater application of VADs than the other two indication segments. It is expected to remain the
Dental Membrane and Bone Graft Substitutes Market to rise to US$ 922.6 Million by 2024
Dental Membrane and Bone Graft Substitutes Market to rise to US$ 922.6 Million b …
Transparency Market Research notes that innovation and expansion into emerging regions have served these companies well in strengthening their hold in the dental membrane and bone graft substitutes market. For instance, Switzerland-based Geistlich Pharma AG - a global manufacturer and supplier of dental products and devices - expanded its operations in Sydney, Australia and New Delhi, India in 2016. The global dental membrane and bone graft substitutes market is expected to
Human Vaccines Market is Estimated to Reach US$ 72.5 Billion by 2024
Human Vaccines Market is Estimated to Reach US$ 72.5 Billion by 2024
The global human vaccines market was valued at US$28.3 bn in 2015 and is estimated to reach US$72.5 bn by 2024, registering an 11.2% CAGR during the forecast period. By age group, pediatric vaccines accounted for a 57.5% share in the global human vaccines market in 2015. Adult vaccines, on the other hand, are expected to expand at a 13.2% CAGR from 2016 to 2024. Based on product, the pneumococcal segment

All 5 Releases


More Releases for Ascariasis

Ascariasis Treatment & Management Market Current Trends and Future Aspect Analys …
Ascariasis is one of the most common helminthic infections in humans worldwide. The diseases is caused by the Ascaris lumbricoids, the largest nematode residing in the alimentary canal of humans. Ascariasis is endemic in the tropical and subtropical regions of the world with low standard of public health and hygiene. The center for diseases control and prevention (CDC) states that, approximately, 0.8-1.2 billion of the global population is infected with
Ascariasis Treatment & Management Market: Upcoming Demands and Growth Analysis 2 …
Ascariasis is one of the most common helminthic infections in humans worldwide. The diseases is caused by the Ascaris lumbricoids, the largest nematode residing in the alimentary canal of humans. Ascariasis is endemic in the tropical and subtropical regions of the world with low standard of public health and hygiene. The center for diseases control and prevention (CDC) states that, approximately, 0.8-1.2 billion of the global population is infected with
Ascariasis Treatment & Management Market - Market Growing at a Healthy Rate | 20 …
Ascariasis is one of the most common helminthic infections in humans worldwide. The diseases is caused by the Ascaris lumbricoids, the largest nematode residing in the alimentary canal of humans. Ascariasis is endemic in the tropical and subtropical regions of the world with low standard of public health and hygiene. The center for diseases control and prevention (CDC) states that, approximately, 0.8-1.2 billion of the global population is infected with
Research Delivers Insight into the Global Outlook for Ascariasis Treatment & Man …
Ascariasis is one of the most common helminthic infections in humans worldwide. The diseases is caused by the Ascaris lumbricoids, the largest nematode residing in the alimentary canal of humans. Ascariasis is endemic in the tropical and subtropical regions of the world with low standard of public health and hygiene. The center for diseases control and prevention (CDC) states that, approximately, 0.8-1.2 billion of the global population is infected with
Ascariasis Treatment & Management Market Research Report Forecast to 2025
Ascariasis is one of the most common helminthic infections in humans worldwide. The diseases is caused by the Ascaris lumbricoids, the largest nematode residing in the alimentary canal of humans. Ascariasis is endemic in the tropical and subtropical regions of the world with low standard of public health and hygiene. The center for diseases control and prevention (CDC) states that, approximately, 0.8-1.2 billion of the global population is infected with
Ascariasis Treatment & Management Market: Upcoming Demands and Growth Analysis
Ascariasis is one of the most common helminthic infections in humans worldwide. The diseases is caused by the Ascaris lumbricoids, the largest nematode residing in the alimentary canal of humans. Ascariasis is endemic in the tropical and subtropical regions of the world with low standard of public health and hygiene. The center for diseases control and prevention (CDC) states that, approximately, 0.8-1.2 billion of the global population is infected with